Genetic polymorphism of miR-196a as a prognostic biomarker for early breast cancer

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2943-2950

  Lee, Soo Jung ^a   Seo, Jong Won ^a   Chae, Yee Soo ^a   Kim, Jong Gwang ^a   Kang, Byung Woog ^a   Kim, Wan Wook ^b   Jung, Jin Hyang ^b   Park, Ho Yong ^b   Jeong, Ji Yun ^a   Park, Ji Young ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Department of Surgery ^*  (South Korea)

Author keywords

Breast cancer; MicroRNA; miR 196a; Prognosis; rs11614913

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; MICRORNA; MICRORNA 196A; PROGESTERONE RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; MIRN196 MICRORNA, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER MODEL; DISEASE FREE SURVIVAL; EARLY BREAST CANCER; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE OVEREXPRESSION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CANCER GRADING; GENETICS; MIDDLE AGED; MIR-196A; MORTALITY; PATHOLOGY; PROGNOSIS; RS11614913; SURVIVAL RATE; TUMOR RECURRENCE; YOUNG ADULT;

BREAST CANCER; MICRORNA; MIR-196A; PROGNOSIS; RS11614913;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84906328265     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472): 1687-1717, 2005.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2): 281-297, 2004.
3. Chang SS, Jiang WW, Smith I, Poeta LM, Begum S, Glazer C, Shan S, Westra W, Sidransky D and Califano JA: MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 123(12): 2791-2797, 2008.
4. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR and Israel MA: Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67(6): 2456-2468, 2007.
5. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R and Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72(5-6): 397-402, 2007.
6. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM and Harris CC: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299(4): 425-436, 2008.
7. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3(5): 317-324, 2006.
8. Meister G and Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature 431(7006): 343-349, 2004.
9. Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L, Calin GA, Hao X, Wei Q, Zhang W and Chen K: An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res 15(19): 6292-6300, 2009.
10. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ and Weidhaas JB: A SNP in a LET-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 68(20): 8535-8540, 2008.
11. Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu H, Liu P, Hao X, Zhang W and Chen K: Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci USA 108(33): 13653-13658, 2011.
12. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH and van de Vijver MJ: WHO classification of tumours of the breast. Lyon: IARC, 2012
13. Singletary SE and Connolly JL: Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56(1): 37-47, 2006.
14. Jung JH, Chae YS, Moon JH, Kang BW, Kim JG, Sohn SK, Park JY, Lee MH and Park HY: TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J Cancer Res Clin Oncol 136(5): 685-694, 2010.
15. TTian T, Shu Y, Chen J, Hu Z, Xu L, Jin G, Liang J, Liu P, Zhou X, Miao R, Ma H, Chen Y and Shen H: A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 18(4): 1183-1187, 2009.
16. Hu Z, Liang J, Wang Z, Tian T, Zhou X, Chen J, Miao R, Wang Y, Wang X and Shen H: Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat 30(1): 79-84, 2009.
17. Adamus G, Brown L, Schiffman J and Iannaccone A: Diversity in autoimmunity against retinal, neuronal, and axonal antigens in acquired neuro-retinopathy. J Ophthalmic Inflamm Infect 1(3): 111-121, 2011.
18. Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, Zeng Y, Miao R, Jin G, Ma H, Chen Y and Shen H: Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 118(7): 2600-2608, 2008.
19. Zhu L, Chu H, Gu D, Ma L, Shi D, Zhong D, Tong N, Zhang Z and Wang M: A functional polymorphism in miRNA-196a2 is associated with colorectal cancer risk in a Chinese population. DNA Cell Biol 31(3): 350-354, 2012.
20. Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T and Zhu Y: microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res 69(14): 5970-5977, 2009.
21. Kim K, Madak-Erdogan Z, Ventrella R and Katzenellenbogen BS: A MicroRNA196a2∗ and TP63 circuit regulated by estrogen receptor-alpha and ERK2 that controls breast cancer proliferation and invasiveness properties. Hormones Cancer 4(2): 78-91, 2013.
22. Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K and Gerber B: Inhibin/activin subunits (inhibin-alpha,-betaA and-betaB) are differentially expressed in human breast cancer and their metastasis. Oncol Rep 13(1): 81-88, 2005.
23. McKiernan E, McDermott EW, Evoy D, Crown J and Duffy MJ: The role of S100 genes in breast cancer progression. Tumour Biol 32(3): 441-450, 2011.
24. Christensen BC, Avissar-Whiting M, Ouellet LG, Butler RA, Nelson HH, McClean MD, Marsit CJ and Kelsey KT: Mature microRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer. Clin Cancer Res 16(14): 3713-3720, 2010.
25. Peng S, Kuang Z, Sheng C, Zhang Y, Xu H and Cheng Q: Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig Dis Sci 55(8): 2288-2293, 2010.
26. Urruticoechea A, Smith IE and Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28): 7212-7220, 2005.
27. de Azambuja E, Cardoso F, de Castro G Jr., Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ and Paesmans M: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer 96(10): 1504-1513, 2007.
28. Paik S: Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12(6): 631-635, 2007.
29. Lyman GH, Cosler LE, Kuderer NM and Hornberger J: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109(6): 1011-1018, 2007.
30. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ and van't Veer LJ: The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 21(4): 717-722, 2010.